Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine in Obsessive-compulsive Disorder
NCT07111988Phase 2Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of valbenazine in obsessive compulsive disorder (OCD) (2 arms), sponsored by University of Chicago. Primary endpoint: Yale-Brown Obsessive-Compulsive Scale at 14 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
valbenazine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT07111988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111988.